Could Early Tirzepatide Alter the Course of Type 2 Diabetes?

[ad_1]

(MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967

Author :

Publish date : 2026-06-29 15:57:00

Copyright for syndicated content belongs to the linked Source.